$75M Gift to Establish Center for Blood Cancers at NYU Langone Health Center
Owing to an anonymous $75 million gift, New York University (NYU) Langone Health and its Laura and Isaac Perlmutter Cancer Center will establish…
News
Real-world Data Supports Use of Oral Triple Combination in Treating Advanced Multiple Myeloma, Study Finds
Real world data from multiple myeloma patients in Hungary supports the use of a triple combination regimen — Ninlaro (ixazomib), Revlimid (lenalidomide), and…
Isatuximab Extends Time Without Cancer Progression in Phase 3 Trial of Multiple Myeloma
Adding isatuximab to a standard of care treatment of Pomalyst (pomalidomide) and low-dose dexamethasone prolonged the time without cancer progression in adults with relapsed…
Thalidomide at 100 mg Shows Benefits as Maintenance Therapy in Multiple Myeloma Patients in Trial
A maintenance treatment with thalidomide at 100 mg a day was safe and seen to delay disease progression by more than three years in multiple myeloma…
Donation Will Establish Center for Multiple Myeloma Research in UK
Thanks to a £10 million donation (about $13,000,000), Imperial College London will establish a center for multiple myeloma research at the institution’s Hammersmith…
Measuring Blood Vessel Activity May Predict Multiple Myeloma Prognosis
A panel of blood markers that identifies tumors with more active blood vessels may help stratify multiple myeloma patients according to their risk, a study found.
Single-cell Profiling in Multiple Myeloma May Improve Diagnosis, Treatment, Study Suggests
Analysis of thousands of individual cells in multiple myeloma patients allows for a much more precise diagnosis — distinguishing asymptomatic, early-stage patients from those…
clonoSEQ Assay Now Covered by Medicare for Multiple Myeloma and Acute Lymphoblastic Leukemia
The clonoSEQ Assay — a test that detects cancer cells present in very small numbers in a patient’s bone marrow — will now be covered…
FDA Asked to OK Darzalex as Combo Therapy for Newly Diagnosed Group of Multiple Myeloma Patients
Janssen Biotech has asked that the U.S. Food and Drug Administration to expand the label for Darzalex (daratumumab) to include its use, in…
Recruitment Begins in Phase 1 Trial of C-CAR088 for Multiple Myeloma
A Phase 1 trial in China is recruiting multiple myeloma patients who failed prior treatments to study Cellular Biomedicine…
Recent Posts
- Tuspetinib study in newly diagnosed AML moves to higher dose
- Low muscle mass linked to worse outcomes with chemoradiotherapy
- Dordaviprone under FDA priority review for aggressive glioma type
- FDA decision on linvoseltamab in treating RRMM expected in July
- CUSP06 put on FDA fast track for platinum-resistant ovarian cancer